Shares in Karo Bio AB gained almost 30 percent this week on news that the company's lead drug candidate, the thyroid hormone receptor agonist eprotirome (KB2115) attained the primary endpoints in a Phase IIb trial in patients with elevated blood lipids who already were receiving statins. (BioWorld International) Read More
